Zydelig – Idelalisib

Zydelig is indicated in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):

• who have received at least one prior therapy, or

• as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies .

Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment